Sperling Prostate Center Blog A First-of-its-Kind Vaccine to Prevent Prostate Cancer Recurrence

Here is fantastic news for men who undergo an initial treatment for localized prostate cancer! In November, 2020 the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to RV001, an investigational vaccine against prostate cancer recurrence after primary treatment. RV001 is manufactured by a Swedish pharmaceutical company called RhoVac. Let’s look at the The post A First-of-its-Kind Vaccine to Prevent Prostate Cancer Recurrence appeared first on Sperling Prostate Center.